Biogen Withdrawal from the Jefferies Healthcare Conference
Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that it will not participate in the Jefferies Healthcare Conference on Wednesday, June 7, 2023.
About Biogen
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
Contact:
Chuck Triano
Investor Relations
Biogen
781.464.2442
